Effect of Vitamin D Supplementation on Bone Mass in Infants With 25-Hydroxyvitamin D Concentrations Less Than 50 nmol/L: A Prespecified Secondary Analysis of a Randomized Clinical Trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Who Took Part

According to the abstract, 866 infants were involved.

The age groups tagged for this paper are infants, both men and women.

In this prespecified secondary analysis of a double-blinded randomized clinical trial, conducted from March 2016 to March 2019 in a single center in Greater Montreal, Quebec, Canada, a consecutive sample of 139 healthy term singletons were recruited from 866 infants screened for vitamin D status at birth.

How the Study Was Run

In design terms this was a randomized and double-blind study.

The infants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Neither the infants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Data were analyzed from June 2021 to November 2022.

Capillary blood was collected 24 to 36 hours after birth to measure serum total 25(OH)D concentrations.

What Was Measured

PubMed files the paper under topics including Dietary Supplements, Bone Density, Vitamin D Deficiency, Vitamin D, Cholecalciferol and Absorptiometry, Photon.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc in 866 infants.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (JAMA pediatrics), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.